Intrommune Therapeutics to Present at BIO Digital 2021
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. The event will be live June 10-11 & 14-18, 2021.
Michael Nelson, JD, Co-Founder and CEO will provide an overview of Intrommune’s core technology for the treatment of peanut and other food allergies. The presentation will focus on lead product INT301, Intrommune’s peanut allergy treatment administered daily through the brushing of teeth, and the oral mucosal immunotherapy (OMIT) platform upon which the treatment is based.
“Considering the amount of progress we have made over the last year, we are very excited to be participating in the 2021 virtual BIO Digital meeting,” said Michael Nelson, CEO, Intrommune Therapeutics. “The initiation of our phase I trial of INT301 for peanut allergic patients marks a significant accomplishment in our timeline, and represents a milestone toward our ultimate goal of developing safe and effective options for food allergy sufferers so they and their loved ones can live their lives without fear.”
Registered attendees can view Mr. Nelson’s corporate overview here, and can arrange partnering meetings with Intrommune using the BIO One-on-One Partnering™ system. Requests for virtual partner meetings can be made here.